Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Marta Llauradó Fernández, Gabriel E. DiMattia, Amy Dawson, Sylvia Bamford, Shawn Anderson, Bryan T. Hennessy, Michael S. Anglesio, Trevor G. Shepherd, Clara Salamanca, Josh Hoenisch,

PubMed · 2016 · 45 citations · 38 references

Concepts

Abstract

mutations, were highly sensitive to MEKi. Drug anti-proliferative efficacy correlated with the degree of inhibition of ERK phosphorylation, with trametinib being the most potent agent. Differences in MEKi efficacy were observed in LGSC cell lines. Trametinib showed the greatest anti-proliferative effects. This study serves as a basis for much needed future research on MEKi drug efficacy in LGSC.

References

38